Pharmaceutical service GoodRx collaborates with Novo Nordisk to reduce costs of weight management medications
In a move aimed at making diabetes treatment more affordable, GoodRx and Novo Nordisk have partnered to offer discounts on two widely prescribed medications: Ozempic and Wegovy.
The collaboration, according to Wendy Barnes, President and Chief Executive Officer of GoodRx, is a significant step forward in making these treatments more accessible. Dave Moore, Executive Vice President of US Operations at Novo Nordisk Inc, echoed similar sentiments, stating that the partnership aims to reach those seeking savings and support from GoodRx.
For patients searching for Ozempic or Wegovy on GoodRx, they will be able to see and apply available discounts. To qualify, patients must have a valid prescription for either medication and typically do not need insurance to use GoodRx discounts.
GoodRx users who qualify can access Novo Nordisk's manufacturer-sponsored savings directly from the platform. This includes the key takeaway for consumers: checking GoodRx could offer new discounts, making treatment more affordable for Ozempic and Wegovy.
The Ozempic self-pay offer for type 2 diabetes patients at an unprecedented price is part of the collaboration. The savings program for these medications will be integrated directly into the GoodRx platform. Without insurance, the list price for one of these drugs is around $1,000 per month. However, through GoodRx, patients can access reduced prices for Ozempic and Wegovy at the pharmacy counter, with a month's supply costing $499.
Novo Nordisk's goal is to expand access to Ozempic and Wegovy using GoodRx's large consumer base. The initiative enables GoodRx patients to access Novo Nordisk's authentic GLP-1 medicines, along with supporting the new Ozempic self-pay offer for type 2 diabetes patients.
The partnership between GoodRx and Novo Nordisk is intended to help bring down the costs of these medications. Furthermore, the new program will help reduce the out-of-pocket burden for eligible patients. The GoodRx platform is designed to deliver savings at scale, bridging gaps in coverage and ensuring more people can get the care they deserve.
In summary, the partnership between GoodRx and Novo Nordisk offers a promising solution for patients seeking affordable treatment options for Ozempic and Wegovy. By checking GoodRx, patients can access discounted prices and make these treatments more accessible.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
